Daily Sepsis Research Analysis
Analyzed 31 papers and selected 3 impactful papers.
Summary
Analyzed 31 papers and selected 3 impactful articles.
Selected Articles
1. Dual targeting of NCF1 and NLRP3 by roburic acid orchestrates redox homeostasis and inhibits macrophage death in septic lung injury.
In murine CLP sepsis models, roburic acid delivered via nanoparticles attenuated lung injury and improved survival. Chemical proteomics identified dual intracellular targets—NLRP3 (blocking inflammasome assembly) and NCF1 (inhibiting NOX2 assembly)—thereby restoring redox homeostasis and suppressing pyroptosis and ferroptosis.
Impact: This study uncovers a dual-target small molecule strategy that simultaneously blocks inflammasome activation and rebalances redox signaling, addressing two converging pathways of septic lung injury with survival benefit in vivo.
Clinical Implications: While preclinical, dual inhibition of NLRP3 and NOX2 suggests a future therapeutic avenue for sepsis-associated acute lung injury, potentially complementing supportive care by directly reducing macrophage-mediated inflammatory cell death.
Key Findings
- RBA-NPs reduced lung injury and improved survival in CLP-induced sepsis models.
- Chemical proteomics and CETSA identified NLRP3 and NCF1 as direct intracellular targets.
- RBA blocked NLRP3 inflammasome assembly via NACHT domain interaction and suppressed pyroptosis.
- RBA inhibited NOX2 assembly through NCF1 binding, restoring redox balance and limiting ferroptosis.
Methodological Strengths
- Integrated multi-modal mechanistic approach (single-cell analysis, chemical proteomics, CETSA) with in vivo validation.
- Nanoparticle delivery system enabling pharmacologic efficacy assessment in clinically relevant CLP models.
Limitations
- Preclinical animal models may not fully recapitulate human sepsis heterogeneity.
- Pharmacokinetics, safety, and dosing of RBA in humans are unknown.
Future Directions: Conduct pharmacokinetic/toxicology studies and test efficacy in large-animal models; stratify by inflammatory endotypes and evaluate combination therapy with standard care.
Sepsis-associated acute lung injury (ALI) is characterized by excessive inflammation and macrophage death, yet precise therapeutic targets remain limited. Single-cell sequencing analysis indicates that, with progression of sepsis-induced lung injury, macrophages exhibit diverse cell-death programs with prominent enrichment of pyroptosis-related signatures. Here, we identify Roburic acid (RBA) as a potent inhibitor of septic ALI and elucidate its mechanism using a nanoparticle delivery system (RBA-NPs). We demonstrate that RBA-NPs significantly attenuate lung injury through a bioactive lipid compound library screening and improve survival in cecal ligation and puncture (CLP)-induced sepsis models. Mechanistically, using chemical proteomics and cellular thermal shift assays, we identify NLRP3 and NCF1 as direct intracellular targets of RBA. Primarily, RBA interacts with the NACHT domain of NLRP3 to directly block inflammasome assembly and pyroptosis. Furthermore, RBA binds to NCF1 to inhibit NADPH oxidase 2 assembly; this restores redox homeostasis, which not only reinforces the suppression of pyroptosis but also confers additional protection by inhibiting lipid peroxidation-mediated ferroptosis. Our study reveals a comprehensive therapeutic strategy where RBA targets the NLRP3 inflammasome while coordinating redox homeostasis via NCF1 to resolve septic lung injury.
2. 7-days versus 14-days antibiotic therapy in uncomplicated culture proven neonatal sepsis: a randomized control assessor-blinded trial.
In a single-center randomized assessor-blinded non-inferiority trial of 140 neonates with uncomplicated culture-proven sepsis, 7-day antibiotic therapy achieved similar (low) relapse rates as 14 days, with shorter hospitalization and reduced respiratory support requirements.
Impact: This pragmatic RCT directly informs antibiotic stewardship in neonatal sepsis by demonstrating that therapy duration can be safely reduced without increasing relapse.
Clinical Implications: For uncomplicated neonatal sepsis (excluding CNS, staphylococcal, and fungal infections), a 7-day course may be sufficient, potentially reducing hospital stay, invasive support, antimicrobial exposure, and resistance selection.
Key Findings
- 140 neonates with uncomplicated culture-proven sepsis were randomized to 7 vs 14 days of antibiotics.
- The 7-day group had shorter hospital stay and required less respiratory support (p < 0.05).
- Both groups had low probable relapse with no fatalities or definitive relapses.
- Klebsiella pneumoniae was the predominant pathogen.
Methodological Strengths
- Randomized, assessor-blinded non-inferiority design with predefined margin and follow-up.
- Systematic exclusions and standardized reassessment before randomization.
Limitations
- Single-center study with modest sample size may limit generalizability.
- Exclusion of meningitis, staphylococcal, and fungal infections narrows applicability.
Future Directions: Multicenter trials to confirm non-inferiority across diverse settings and pathogens; evaluate stewardship outcomes and long-term neurodevelopment.
UNLABELLED: The trial aimed to establish the non-inferiority of a 7-day antibiotic therapy for uncomplicated neonatal sepsis when compared to the standard 14-day therapy. This study was a parallel-group, randomized non-inferiority assessor-blinded trial conducted in a tertiary Neonatal Intensive Care Unit in Central India. Neonates weighing ≥ 1000 g with suspected sepsis were screened and those meeting criteria were enrolled. Exclusions included babies with CNS (central nervous system) infections, septic arthritis, and life-threatening congenital malformations. Participants were observed for 7 days on antibiotics and re-evaluated; those with positive blood cultures were then randomized to receive either 7 or 14 days of antibiotics. The primary outcome was the relapse of sepsis, and a sample size of 70 in each arm was calculated based on a non-inferiority margin. Follow-ups were conducted for 48 h post-antibiotic treatment and weekly for 35 days to monitor any recurrence of illness. During the study, 917 babies with suspected sepsis were admitted, of which 256 had culture-positive sepsis. After excluding those with meningitis, staphylococcus, and fungal infections, 140 babies showed improvement at day 5 and were randomized into two groups: one receiving antibiotics for 7 days and the other for 14 days, each consisting of 70 babies. Klebsiella pneumoniae was the prevalent organism. The 7-day group had a shorter hospital stay (p < 0.05) and less respiratory support (p < 0.05). Outcomes revealed a low incidence of probable relapse in both groups, with no fatalities or definitive relapses recorded. CONCLUSIONS: A 7-day antibiotic regimen for uncomplicated neonatal sepsis is not inferior to a 14-day regimen. WHAT IS KNOWN: • Unregulated use of antibiotics can lead to a myriad of problems, especially in neonates. • There is some evidence that uncomplicated neonatal sepsis can be treated with short-course antibiotics. WHAT IS NEW: • Data is lacking-especially from Central India. • This trial checks if it is possible to reduce the duration of antibiotic therapy in uncomplicated neonatal sepsis.
3. Targeted Surface-Enhanced Raman Scattering for Highly Accurate Identification of Bacterial Species and Finding Spectral Signatures with Explainable Artificial Intelligence.
By engineering colloidal Au/Ag nanoparticle SERS substrates and systematically probing ligand chemistry and wavelength dependence within the 500–1300 cm−1 fingerprint region, the study achieved reproducible bacterial spectra and used explainable AI to isolate discriminative spectral signatures for species identification.
Impact: Optimized, interpretable SERS workflows can accelerate rapid, culture-independent bacterial identification, a cornerstone for time-critical sepsis management and antimicrobial stewardship.
Clinical Implications: If validated clinically, this platform could shorten time-to-pathogen identification, enable earlier targeted therapy, and reduce broad-spectrum antibiotic use.
Key Findings
- Reproducible bacterial SERS spectra were obtained using colloidal Au and Ag nanoparticles.
- Ligand effects on plasmonic nanoparticles and excitation wavelength dependence were systematically evaluated for species identification.
- Explainable AI highlighted discriminative spectral fingerprints within 500–1300 cm−1 to support accurate bacterial classification.
Methodological Strengths
- Systematic optimization of nanoparticle ligands and excitation wavelength with reproducible SERS acquisition.
- Use of explainable AI to interpret spectral features, enhancing transparency and potential clinical acceptance.
Limitations
- Clinical validation in real-world specimens and across platforms is not reported.
- Standardization of sample preparation and instrument variability remain potential barriers.
Future Directions: Prospective clinical validation against culture/molecular gold standards, robustness testing across instruments, and workflow integration into sepsis pathways.
The analysis of complex Raman spectra from biological samples has traditionally relied on conventional chemometric-based methods, the performance of which has been further improved by artificial intelligence (AI). The accurate identification of bacteria is critical to preventing sepsis, even in advanced clinical settings. Among several methods, Raman scattering has shown great promise in overcoming the limitations of conventional approaches. Despite this promise, unresolved challenges remain in the optimization of SERS and interpretation of AI algorithms. In this study, we used colloidal Au and Ag nanoparticles (NPs) to obtain reproducible surface-enhanced Raman scattering (SERS) spectra of bacteria. We investigated the effects of ligands on plasmonic NPs and wavelength dependence in SERS-based bacterial identification. The analysis was conducted within the biological fingerprint region of 500-1300 cm